Abstract 1438P
Background
Outcomes for patients (pts) with squamous non-small cell lung cancer (NSCLC) treated with immunotherapy are generally poorer than pts with non-squamous NSCLC and have fewer treatment options. We report an exploratory subgroup analysis of pts with squamous NSCLC who were treated with cemiplimab from two phase 3 clinical trials.
Methods
EMPOWER-Lung 1 (NCT03088540) and EMPOWER-Lung 3 (NCT03409614; part 2) included pts with squamous or non-squamous advanced NSCLC without EGFR, ALK or ROS1 aberrations. In EMPOWER-Lung 1, pts with ≥50% programmed cell death-ligand 1 (PD-L1) were randomized 1:1 to first-line (1L) cemiplimab monotherapy or platinum-doublet chemotherapy (chemo). In EMPOWER-Lung 3, pts irrespective of PD-L1 level were randomized 2:1 to 1L cemiplimab + chemo or placebo + chemo.
Results
In both trials, ∼43% of pts had squamous histology. In EMPOWER-Lung 1, at median follow-up of 37.1 mo, for squamous pts treated with cemiplimab vs chemo, median overall survival (OS) was 22.7 vs 13.5 mo (HR: 0.51; 95% CI: 0.37, 0.69), and median progression-free survival (PFS) was 8.3 vs 5.9 mo (HR: 0.44; 95% CI: 0.32, 0.59). The objective response rate (ORR) was 43.9% vs 22.1%, and the median duration of response (DOR) was 16.0 mo (95% CI: 10.4, 33.0) vs 4.3 mo (95% CI: 4.2, 6.1), respectively. In EMPOWER-Lung 3 part 2, at a median follow-up of 28.4 mo, for squamous pts treated with cemiplimab + chemo vs placebo + chemo, median OS was 22.3 vs 13.8 mo (HR: 0.61; 95% CI: 0.42, 0.87), and median PFS was 8.2 vs 4.9 mo (HR: 0.56; 95% CI: 0.41, 0.78). ORR was 46.6% vs 26.9%, and the median DOR was 13.8 mo (95% CI: 11.0,18.2) vs 11.3 mo (95% CI: 4.2, 21.4), respectively. Patient reported outcomes and safety results will be described for both studies in the presentation.
Conclusions
Subgroup analysis with long-term follow up data from two large phase 3 studies demonstrate improved clinical benefit of cemiplimab as 1L monotherapy or in combination with platinum-doublet chemo over chemo alone in pts with squamous NSCLC. Table: 1438P
EMPOWER-Lung 1† Squamous | EMPOWER-Lung 3 Part 2Squamous | |
Cemiplimab (n=123) vschemo (n=122) | Cemiplimab + chemo (n=133) vsplacebo + chemo (n=67) | |
OS, median, mo | 22.7 vs 13.5 | 22.3 vs 13.8 |
OS HR (95% CI) | 0.51 (0.37, 0.69) | 0.61 (0.42, 0.87) |
PFS, median, mo | 8.3 vs 5.9 | 8.2 vs 4.9 |
PFS HR (95% CI) | 0.44 (0.32, 0.59) | 0.56 (0.41, 0.78) |
ORR, % | 43.9 vs 22.1 | 46.6 vs 26.9 |
DOR, median (95% CI), mo | 16.0 (10.4, 33.0) vs 4.3 (4.2, 6.1) | 13.8 (11.0,18.2) vs 11.3 (4.2, 21.4) |
†PD-L1 ≥50% population. Data cutoff dates: EMPOWER-Lung 1: 4 Mar 2022; EMPOWER-Lung 3 Part 2: 14 June 2022.
Clinical trial identification
NCT03088540; NCT03409614.
Editorial acknowledgement
Medical writing support was provided by John Facciponte, PhD, of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc., and Sanofi.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc.
Funding
Regeneron Pharmaceuticals, Inc., and Sanofi.
Disclosure
A. Sezer: Financial Interests, Institutional, Research Grant: Roche, Merck Sharp & Dohme, Merck Serono, AstraZeneca, Lilly, Novartis, Johnson & Johnson, Regeneron Pharmaceuticals, Inc., Sanofi. S. Kilickap: Financial Interests, Personal, Other, Travel support: Regeneron. M. Gumus: Financial Interests, Institutional, Invited Speaker: Pfizer, Gen Pharmaceuticals, Novartis, Bayer; Financial Interests, Institutional, Advisory Board: Amgen, Roche, BMS, AstraZeneca; Financial Interests, Institutional, Coordinating PI: Amgen; Financial Interests, Institutional, Local PI: Jounce Therapeutics. K.D. Penkov: Financial Interests, Personal, Advisory Board: Nektar Therapeutics; Financial Interests, Personal and Institutional, Local PI: AbbVie, AstraZeneca, Pfizer, Jounce Therapeutics, Polyphor, GSK, Mabscale, Biocad, Sanofi, Novartis, Regeneron Pharmaceutical. M. Ozguroglu: Financial Interests, Personal, Advisory Board, prostate cancer: Astellas; Financial Interests, Personal, Invited Speaker, travel and accommodation: Regeneron; Financial Interests, Personal, Advisory Board, lung cancer meeting: Sanofi. E. Kalinka: Financial Interests, Personal, Advisory Board, advisory board member, clinical trial and lectures honoraria: Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker, lectures and clinical trial honoraria: Merck Sharp and Dohme; Financial Interests, Personal, Invited Speaker, lectures honoraria: GSK, Roche; Financial Interests, Personal, Invited Speaker, lectures honoraria and writing engagement: Sanofi, Regeneron; Financial Interests, Personal, Advisory Board, advisory role, clinical trials honoraria: AstraZeneca; Financial Interests, Personal, Invited Speaker: Gilead, Amgen; Financial Interests, Personal, Ownership Interest: Instytut MSF Sp zoo; Financial Interests, Personal and Institutional, Local PI: AstraZeneca, Roche, Bristol Myers Squibb, Gilead; Financial Interests, Personal, Local PI: Merck Sharp Dohme. D. McIntyre, M. Kaul, R.G.W. Quek, J. Pouliot, F. Seebach, G. Gullo, P. Rietschel: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1453P - Trends in treatment regimens and survival in the use of immune checkpoint inhibitors for lung cancer treatment in the Netherlands from 2016-2020
Presenter: Erick Suazo Zepeda
Session: Poster session 20
1454P - Radiomic analysis predicts response to immunotherapy in metastastic non-small cell lung cancer (mNSCLC): Preliminary results
Presenter: Salvatore Grisanti
Session: Poster session 20
1455P - Nivolumab (nivo) resumption in patients with advanced or metastatic non-small cell lung cancer (aNSCLC): Survival outcomes based on France and Germany real-world data (RWD)
Presenter: Maurice Pérol
Session: Poster session 20
1456P - Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Poster session 20
1457P - Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
Presenter: Marcel Wiesweg
Session: Poster session 20
1459P - Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
Presenter: Caicun Zhou
Session: Poster session 20
1460P - GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Francisco Aparisi Aparisi
Session: Poster session 20
1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)
Presenter: Toublanc Anne-Claire
Session: Poster session 20
1463P - IL-6 triggers chemoimmunotherapy resistance by creating immunosuppressive tumor microenvironment in non-small cell lung cancer
Presenter: Yaning Yang
Session: Poster session 20